Cetuximab

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity[1].

Product Specifications

CAS Number

[205923-56-4]

Product Name Alternative

C225; IMC-C225

UNSPSC

12352203

Target

EGFR; Radionuclide-Drug Conjugates (RDCs)

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Anti-EGFR_Neutralizing_Antibody.html

Purity

99.70

Solubility

H2O

Smiles

[Cetuximab]

Molecular Weight

(145.54 kDa)

References & Citations

[1]Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1 (11) :1311-8.|[2]Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.|[3]Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59 (8) :1935-40.